Current Pharmaceutical Design

Novel Data on the Prevalence, Identification, Scouting, and Treatment of Familial Hypercholesterolaemia
pp. 3597-3598(2)
Authors: Doumas, Michael; Imprialos, Konstantinos; Stavropoulos, Konstantinos; Athyros, Vasilios G.

New Horizons in the Pathogenesis, Pathophysiology and Treatment of Familial Hypercholesterolaemia
pp. 3599-3604(6)
Authors: Viigimaa, Margus; Heinsar, Silver; Lovic, Dragan; Katsimardou, Alexandra; Piperidou, Alexia; Duishvili, Davit

Prevalence, Identification, and Scouting for Familial Hypercholesterolaemia Including Registries
pp. 3605-3615(11)
Authors: Florentin, Matilda; Kostapanos, Michael S.; Elisaf, Moses S.; Liberopoulos, Evangelos N.

Multimodal Treatment of Homozygous Familial Hypercholesterolemia
pp. 3616-3621(6)
Authors: Gossios, Thomas; Zografou, Ioanna; Simoulidou, Veta; Pirpassopoulou, Athina; Christou, Konstantinos; Karagiannis, Asterios

Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives
pp. 3622-3633(12)
Authors: Tsouka, Aikaterini N.; Tellis, Constantinos C.; Tselepis, Alexandros D.

Lipoprotein Apheresis and PCSK9-Inhibitors. Impact on Atherogenic Lipoproteins and Anti-Inflammatory Mediators in Familial Hypercholesterolaemia
pp. 3634-3637(4)
Authors: Stefanutti, Claudia; Zenti, Maria G.

Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation
pp. 3638-3646(9)
Authors: Athyros, Vasilios G.; Katsiki, Niki; Dimakopoulou, Aikaterini; Patoulias, Dimitrios; Alataki, Sofia; Doumas, Michael

Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia
pp. 3647-3653(7)
Authors: Papademetriou, Vasilios; Stavropoulos, Konstantinos; Papadopoulos, Christodoulos; Koutsampasopoulos, Konstantinos; Dimitriadis, Kiriakos; Tsioufis, Kostas

The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors
pp. 3654-3657(4)
Authors: Theocharidou, Eleni; Papademetriou, Marianna; Reklou, Andromachi; Sachinidis, Alexandros; Boutari, Chrisoula; Giouleme, Olga

Is very low LDL-C harmful?
pp. 3658-3664(7)
Authors: Faselis, Charles; Imprialos, Konstantinos; Grassos, Haris; Pittaras, Andreas; Kallistratos, Manolis; Manolis, Athanasios

Should we Consider Lipoprotein (a) in Cardiovascular Disease Risk Assessment in Patients with Familial Hypercholesterolaemia?
pp. 3665-3671(7)
Authors: Anagnostis, Panagiotis; Siolos, Pavlos; Krikidis, Dimitrios; Goulis, Dimitrios G.; Stevenson, John C.

Familial Hypercholesterolemia in Children and Adolescents: Diagnosis and Treatment
pp. 3672-3677(6)
Authors: Maliachova, Olga; Stabouli, Stella

Progresses in microRNA Delivery Using Synthetic Nanovectors in Cancer Therapy
pp. 3678-3696(19)
Authors: Javanmardi, Sanaz; Aghamaali, Mahmoud R.; Abolmaali, Samira Sadat; Tamaddon, Ali Mohammad

Emerging Trends in Advanced Nanomaterials Based Electrochemical Genosensors
pp. 3697-3709(13)
Authors: Kaushik, Mahima; Khurana, Sonia; Mehra, Komal; Yadav, Neelam; Mishra, Sujeet; Kukreti, Shrikant

The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials
pp. 3710-3723(14)
Authors: Bakhshayeshkaram, Marzieh; Lankarani, Kamran B; Mirhosseini, Naghmeh; Tabrizi, Reza; Akbari, Maryam; Dabbaghmanesh, Mohammad H.; Asemi, Zatollah